Drug intelligence / Profile preview

Persumac (Mashhad University of Medical Sciences)

Development stage: Unknown
Lead developer: Mashhad University of Medical Sciences
Administration: Oral

Overview

Persumac is an Iranian traditional medicine remedy composed of Sumac (*Rhus coriaria*) and *Bunium persicum* (Black Cumin). It is developed by the Mashhad University of Medical Sciences and is primarily investigated for the management of refractory chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer. The combination is hypothesized to reduce the frequency and severity of nausea and vomiting in both acute and delayed phases following chemotherapy. As a botanical product, it contains a complex mixture of phytochemicals that may exert anti-emetic effects through gastroprotective and potentially neuroprotective pathways.

Brand names: Persumac
Other names: Sumac and Bunium Persicum

Beyond the preview

Go deeper on Persumac (Mashhad University of Medical Sciences).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Persumac (Mashhad University of Medical Sciences).

Explore the full profile